SlideShare a Scribd company logo
1 of 120
Download to read offline
ARTHOPOD VECTOR BORNE
DISEASES
Dr. N.Vinay Kumar
Under the guidance of Dr. J M Pawar sir
ARTHROPOD
• Arthropod is a Greek word meaning Jointe Leg(Arthron:joint,pod:foot)
• It is an invertebrate animal having an exoskeleton, a segmented body and paired
body appendages.
VECTOR
• A vector is an organism that does not cause disease in itself ,but does spread the
parasite to other life forms.
Arthopods of medical importance
Transmission of arthopod vector borne diseases
1)Direct contact-eg.scabies,pediculosis
2)Mechanical trasmission-eg.diarrhoes,dysentry
3)Biological transmission-3 types
a)propagative -eg.plague bacilli in ratflea
b)cyclo-developmental-eg.filarial larva in culex
c)cyclo-propagative -eg.malarrial parasite in anopheles
Diseases transmitted by vectors
ANOPHELES
• Malaria
• Lymphatic filariasis
CULEX
• Lymphatic filariasis
• Japanese encephalitis
AEDES
• Yellow fever
• Dengue fever
• Chikungunya
• Zika
MANSONIA
• Lymphatic filariasis
TseTse fly
• African sleeping sickness
BLACK FLY
• Onchocerciasis
SAND FLY
• Kala azar
• sand fly fever
• oryza fever
HORSE FLY
• Loiasis
HARD TICK
• KFD
• tick paralysis
• Tularemia
• Lyme disease
• Babeseosis
SOFT TICK
• Q fever
• Relapsing fever
REDUVID BUG
• Chagas disease
RAT FLEA
• Plague
• Endemic typhus
LOUSE
• Relapsing fever
• Epidemic typhus
• Trench fever
MITE
• rickettsial pox
• scrub typhus
Diseases transmitted by mosquitos
• Malaria
• Lymphatic filariasis
• Japanese encephalitis
• Yellow fever
• Dengue fever
• Chikungunya
• Zika
MOSQUITO
Malaria
• Name is derived from Italian Mal’ aria or bad air
• 1880 - Charles Louis Alphose Lavern discovered malarial parasite in wet mount.
• 1898 - Roland Ross - Life cycle of parasite transmission, wins Nobel Prize in 1902
• Malaria is a vector-borne infectious disease caused by single-celled protozoan parasites
of the genus Plasmodium.
• Malaria is transmitted from person to person by the bite of female mosquitoes.
Etiology of Malaria
Four Species known to infect Man
1 Plasmodium vivax
2 P.ovale
3 P.malariae
4 P.falciparum
LIFE CYCLE
clinical manifestations
UNCOMPLICATED MALARIA
First symptoms are non specific:
• Headache, Lassitude, Fatigue
• Abdominal discomfort, muscle and joint aches, diarrhea
• Followed by fever(irregular at first), chills, rigors, perspiration, anorexia . In some
cases palpable spleen and slight enlargement of liver are also present
• Nausea,vomiting, & orthostatic hypotension are common
Signs:
• Anemia, splenomegaly, hepatomegaly
SEVERE FALCIPARUM MALARIA
• Unarousable Coma / cerebral malaria, convulsions
• Renal Impairment
• Noncardiogenic pulmonary edema
• Liver Dysfunction
• Hypoglycemia
• Metabolic acidosis/acidemia
• Hematological abnormality like hemoglobinuria, normocytic anemia, bleeding,DIC
• Other complications like jaundice, extreme weakness,hyperparasitemia, impaired
consciousness
• Hypotension/shock
complications
• Cerebral malaria
• Renal failure
• Non cardiogenic pulmonary oedema
• Hypoglycemia
• Acidosis
• Haematologic abnormalities
• Algid malaria
• Tropical splenomegaly
• Quartan malarial nephropathy
CEREBRAL MALARIA
• Coma is characteristic and ominous feature of falciparum malaria
• Manifests as diffuse encephalopathy
• No signs of meningeal irritation
• Muscle tone : May be Increased/ Decreased
• Tendon reflexes : Variable, Plantars : Equivocal.
• Abdominal & cremasteric reflexes are absent
• Fundus : Retinal hemorrhages, discreet spots ofretinal opacification, papilledema,
cotton wool spots
• Convulsions :In children, usually generalised, often repeated
• Residual neurological deficit(Hemiplegia, CP, cortical blindness, deafness, impaired
cognition and learning) seen in children who survive cerbral malaria
Diagnosis
Clinical
• Fever, sweat, chills, headache and muscle pain
Serology
• PCR
• ELISA
Blood Film (gold standard)
• Banana-shaped intraerythrocytic gametocytes identify P. falciparum
• Enlarged erythrocytes with Schuffner’s dots are characteristics of P. vivax
• Schuffner’s dots in ovale-shaped red blood cells are characteristic of P. ovale
• Band-form trophozoites are seen in P. malariae
TREATMENT
All Plasmodium species except chloroquine resistant falciparum malaria
Oral Drug of Choice
• Chloroquine phosphate10 mg base/kg
(maximum: 600 mg base) then 5 mg base/kg (maximum: 300 mg base),
6 hr later,24 and 48 hr.
Parenteral Drug of Choice
• Quinidine gluconate10 mg/kg loading dose(maximum: 600 mg) over 1-2 hr, then 0.02
mg/kg/min continuous infusion until oral therapy can be started Or
• Quinine dihydrochloride 20 mg/kg loading dose over 4 hr, then 10 mg/kg over 2-4 hr q8h
(maximum: 1,800mg/24 hr) until oral therapy can be started
Chloroquine resistant Faliciparum Malaria
Oral Regimen of Choice
 Quinine sulfate 30 mg/kg/24 hr divided in three doses for 3-7 days (maximum:
650 mg/dose) plus Tetracycline 20 mg/kg/24 hr divided in four doses for 7 days
(maximum: 250 mg/dose).
• Mefloquine hydrochloride15 mg PO followed by 10 mg/kg PO 8-12 hours later
(maximum: 1,250 mg) for 1 day.
Parenteral
• Quinidine gluconateSame as for chloroquine-sensitive P. Falciparum
or
• Quinine dihydrochlorideSame as for chloroquine-sensitive P. falciparum.
Prevention of Relapses
Plasmodium vivax and Plasmodium ovaleOnly
• Primaquine phosphate
ARTEMISINS
• Artemisinin derivatives clear parasitemia morerapidly than quinine . They
are active against abroader life-cycle range of blood stage parasitesthan
quinine and they are active against gametocytes .
• Artemisinin derivatives include artesunate , artemether and artemotil.
Artesunate is thepreferred artemisinin; clinical experience with
artemether and artemotil drugs is limited and they should not be used
for treatment of severedisease.
The standard dosing regimen for intravenous artesunate consists of five
doses:
• 2.4 mg/kg as the first dose, followed by
• 2.4 mg/kg at 12 and 24 hours, followed by
• 2.4 mg/kg once daily
Lymphatic Filariasis
• Filariasis is the pathological condition caused by infection of filarial nematodes transmitted
by different vectors.
• Infection with 3 closely related Nematodes
1) Wuchereria bancrofti
2) Brugia malayi
3)Brugia timori
Vectors of lymphatic filariasis
The major vectors of W. bancrofti are mosquitoesof the genus Culex , Anopheles and Aedes.
The vectors of B. malayi are transmitted by Mansonia; in some areas,anopheline mosquitoes.
life cycle
Clinical manifestations
• Asymptomatic amicrofilaraemia :exposed people in endemic area do not show Mf or clinical
manifestation of disease.
• Asymptomatic microfilaraemia: blood is positive for Mf, but no symptoms. carriers.
• Stage of acute manifestation: recurrent episode of acute inflammation in lymph gland and
vessels.Filarial fever, lymphangitis, lymphadenitis,lymphoedema and epididymoorchitis.
• Stage of chronic obstructive lesion:develops 10- 15 yrs after acute attack.
mainly due to fibrosis and obstruction of lymphatic vessel, causing permanent structural
change.
Hydrocele, elephantiasis and chyluria.
LABORATORY DIAGNOSIS
• Samples includes :
Peripheral blood , Chylous urine, Exudate of lymph varix, Hydrocele fluid,Lymph
node biopsy, skin specimen
• Microscopic examination : It deals with the detection of microfilariae.
• Macroscopic examination : detection of adult worm ( lypmh node biopsy )
• Haematological examination : eosoinophilic count is done.
• Serological test : Complement fixation test is performed.
• Intradermal test : immediate hypersensitivity test. Filarial antigen is injected
on skin. After 30 minutes a wheal over 2 cm appears.
Treatment
• Diethyl carbamazepine is the drug of choice for Lymphatic filariasis.
• It is filaricidal in action.
1st day—50 mg .
2nd day---50 mg tid .
3rd day--- 100 mg tid.
4th day to 21st day– 5mg/kg /day in 3 divided doses.
• Use of tetracycline to kill the adult worm & to kill wolbachia bacteria which is having a
symbiotic relation with W.bancrofti.
• Other drugs include: Ivermectin-single oral dose-150μg/kg is used to destroy the Mf, but
not the adult worm.
• Recently evaluated drugs include Levamisole, mebendazole and centprazine.
JAPANESE ENCEPHALITIS
• Japanese encephalitis is a mosquito-borne viral infection.
• Japanese Encephalitis is the inflammation of brain,due to Group B Arbo virus transmitted by
Culex mosquitoes.
• It is directly affect to the central nervous system and may cause severe complications.
Agent
Group B Arbo virus in the genus group of Flaviviridae.
Host
All age groups & Both genderMore in children under 15 years of age.
vector
Culex tritaeniorhynchus,c.vishnii
reservoir
Domestic pigs and wild birds(especially herons) are reservoirs of the virus.
Incubation Period
5-15 days.
PATHOGENESIS
clinical features
1. Prodromal stage
2. Acute Encephalitic stage
3. Late stage
Prodromal stageThe onset of illness is usually
acute & the
duration of this stage is usually 1-6 days.
• Fever(38-41’c)
• Headache
• Rigors (Intensive shivering)
• GI disturbances
• Nausea & Vomiting
• Lethargy
Acute Encephalitic stage This stage begins by 3-5th
day
• High grade fever
• Nuchal rigidity
• Convulsions signs of increased ICP
• Unconsciousness
• Dystonia
• Dysphasia
• Hemiplegia
• Quadriplegia
Late stage
• This stage begins when activeinflammation reducedie,the temperature &
ESR touch normal.
• CNS involvement is more in this stage.
• Mental impairment
• Epilepsy
• Behavioural abnormalities.
• The average period between the onset of illness and death is about 9
days .
Treatment
• supportive treatment (anti pyretics,anticonvulsants,diuretics etc)
VACCINATION
3 types of JE vaccines:
1. Mouse Brain-derived Purified &Inactivated Vaccine (Nakayama or
Beijing strain of JE virus)
2. Cell Culture Derived Inactivated JE Vaccine (Beijing P-3 strain)
3. Cell Culture Derived, Live Attenuated Vaccine ( SA 14 – 14 – 2
strain of JE virus)
Yellow Fever
• Yellow fever is a mosquito-borne acute febrile illness accompanied by hepatic
necrosis.
• It occurs mainly in tropical Africa and Latin America.
• It does not exist in India.
• The name has been derived from ‘yellow quarantine flag’ used by the ships during
17th century to warn the presence, on board of this infection.
• Yellow fever occurs in 2 major forms: urban and jungle (sylvatic) cycle.
• In the urban cycle, man serves both as reservoir and as definitive host, the virus
being transmitted by Aedes aegypti mosquito
• In the forest or sylvatic cycle, wild monkeys act as reservoirs and several species of
forest mosquitos are vectors. Human cases occur only when humans trespass into
the forest or when monkeys raidvillages
Pathogenesis
• After introduction into the skin by the mosquito-bite, the virus
multiplies locally and spreads to the local lymphnodes where it
multiplies.
• From the lymphnodes, it enters the circulating blood. The virus starts
appearing in blood 3-6 days after the bite ofinfected mosquito and
viraemia lasts for 4-5 days.
• From blood, the virus becomes localised in the liver,spleen, kidney,
bonemarrow and myocardium, where it may persist for days.
• The lesions of yellow fever are due to the localization and
propagation of the virus in a particular organs.
Clinical features
• After an incubation period of 3-6 days, patient develops fever with
chills, headache, myalgia and vomiting.
• Most cases are mild in nature, especially in the endemic areas, in
whom the disease may present as undifferentiated fever without
jaundice.
• The pulse is usually slow despite a high temperature.
• In 15-20% of cases, the disease progresses to a more serious form with
jaundice, albuminuria, renal failure and haemorrhagic manifestations
and the patient may die of hepatic and renal failure.
Laboratory diagnosis
Detection of viral antigen
• Viral antigen or nucleic acid can be detected in tissue specimen using ELISA, PCR, and
immunohistochemistry
Isolation of virus
• Virus can be isolated from blood in the first 4 days after onset or from postmortem tissue
by intracerebral inoculation of mice or inoculating cell lines
Postmortem diagnosis
• There is severe midzonal degeneration, necrosis andacidophilic inclusion bodies seen in
the liver
Serology
• During first week of illness, IgM antibody can be detected by ELISA
Prophylaxis
• There is no antiviral drug against yellow fever
• The control of urban yellow fever can be achieved by eradicating the
vector mosquito
• Two vaccines have been developed for human use
1. The french neurotropic vaccine (Dakar) produced from infected
mouse brain.
2. 17D vaccine developed by Theiler in 1937 .
• Live attenuated vaccine “non virulent strain cultivated on chick
embryo & subsequently freeze dried”. Vaccine is stored at -25°C.
• Single dose, 0.5ml, S.C. injection.
• effectiveness start after 10days & persists for 10 years & then
reimmunization
is required.
VACCINATION CERTIFICATE
a. Is required from all international travelers including childrencoming
from or going to endemic areas "Yellow Fever belt".
b. Validity starts 10 days after primo-vaccination & lasts for 10 ys.
c. Validity starts on same day after re-vaccination & lasts for 10 ys.
d. If no certificate is available: traveler is isolated for 6 days from date
of leaving endemic area.
Dengue
• Dengue fever is clinically similar to the illness caused by the chikungunya
and O’nyong-nyong viruses.
• Dengue virus is widely distributed in the Caribbean region, south east
asia.
• In India first outbreak of dengue was recorded in 1812.
• In New Delhi, outbreaks of dengue fever reported in 1967,1970,1982,
&1996.
Morphology of Dengue virus
• spherical,Contains a single plus strand of RNA surrounded by a lipid
bilayer.
• The E (envelope), M (membrane) and C (capsid) proteins
Etiology types
• Four distinct antigenically related serotypes ( 1to 4) of dengue virus of the
family flaviviridae are etiologically responsible.
• Infection in human by one serotypes produces life long immunity against
re-infection by the same serotype.
• All 4 types of dengue viruses are present in India.
• Subsequent infection with other serotypes may result in a severe illness i.
e., dengue haemorrhagic fever or dengue shock syndrome.
• Dengue transmitted by infected female Aedes mosquito.
Pathogenesis
1.The virus is inoculated into humans with the mosquito saliva.
2.The virus localizes andreplicates in various organs,for example, local lymph nodes,
liver, spleen and the thymus.
3.The virus is then released from these tissues into theblood.
4.Via the blood, the virus spreads throughout the body to infect other lymphatic
tissues and organs, which is accompanied by symptoms.
5.The mosquito ingests blood containing the virus.
6.The virus replicates in the mosquito midgut. It then escapes into the body cavity, and
later infects the salivary glands.
7.The virus replicates in the salivary glands and when the mosquito bites another
human, the cycle continues.
Clinical features
• The disease may occur in two forms
1. Classical dengue fever (break-bone fever).
2. Dengue in more serious forms with haemorrhagic manifestations (DHF/DSS).
Classical dengue fever
This usually affects older children and adults
• It has relatively benign course with fever, headache, retrobulbarpain, conjunctival infection, pain in
muscles and bones,lymphadenopathy and maculopapular rash
• The fever is typically biphasic (saddle back)
• Incubation period is 5 – 8 days
• A maculopapular rash generally appears on 3rd or 4th day
• The febrile illness lasts for about 10 days after which recovery is generally complete. It is rarely fatal.
Other manifestations
Dengue may also occur in more serious forms, with haemorrhagic
manifestations or with shock.
• DHF/DSS remains mostly confined among children of 5 -10 years age group in
area where multiple dengue viruses cause disease.
• It appers to be hyperimmune response.
• On reinfection with a different serotype of dengue virus, antibody formed
against the first virus reacts with the second serotype virus forming immune
complexes (virus-antibody complex).
• In DHF/DSS, initial symptoms are like those of dengue fever but associated with
haemorrhagic rash, thrombocytopenia and shock
Clinical Case Definition for Dengue Fever
• Classical Dengue fever or Break bone fever is an acute febrile viral
• disease frequently presenting with headaches, bone or joint pain,
• muscular pains,rash,and leucopenia
Clinical Case Definition for Dengue Hemorrhagic Fever
4 Necessary Criteria:
• 1. Fever, or recent history of acute fever
• 2. Hemorrhagic manifestations
• 3. Low platelet count (100,000/mm3 or less)
• 4. Objective evidence of “leaky capillaries:”
elevated hematocrit (20% or more over baseline) ,low albumin, pleural or other effusions
Clinical Case Definition for Dengue Shock Syndrome
4 criteria for DHF
+
Evidence of circulatory failure
Hemorrhagic Manifestations of Dengue
petechiae, purpura, ecchymoses,Gingival bleeding,Nasal bleeding
Hematemesis, melena, hematochezia,Hematuria
Laboratory diagnosis
1)Haematological diagnosis-Thrombocytopenia (1,00,000 cells or less per
mm3),Haemoconcentration (> 20 % rise in haematocrit).
2)Microbiological diagnosis-
• Detection of antibody
• Detection of NS1 antigen
• Isolation of virus
• PCR
Dengue fever Management
• There is no specific antiviral treatment.
• The management is essentially supportive and symptomatic.
• The key to success is frequent monitoring and changing strategies depending on clinical
and laboratory evaluations
• Bed rest, Antipyretics or cold sponging ,Analgesics and mild sedation.
Prophylaxis
• Control measures include elimination of mosquitoes
• No effective vaccine is available
• In order to avoid the DHF/DSS in immunised persons, a live attenuated vaccine containing
all four dengue serotypes is under clinical trials
Chikungunya
• The virus is transmitted by Aedes aegypti.
• Chikungunya is the native name for the disease in which thepatient lies ‘doubled –up’ due to severe joint pains
• First reported Tanzania in 1952
• The virus first appeared in India 1963 when it caused extensive epidemics in Calcutta, Madras, and other areas.
• Outbreaks at irregular intervals along east coast of India and Maharashtra till 1973.
• It remained quiesent and then reappeared in 2006.
• Large outbreak in Andhra and Tamil Nadu which spread to Kerala, Karnataka and Delhi.
• There was a reemergence of the chikungunya virus in Indonesia, Schyecelles, Reunioun island of Indian ocean
and in India(2006-2007)
• due to-
1. Mutation in the E1 glycoprotein of the virus.
2. The virus was being taken up and transmitted byAedes albopiptus.
Cinical manifestations
Incubation period – 2-3 days
• Adults- full blown disease
• Crippling joint pains. Migratory polyarthritis mainly
affects the small joints of the hands and the wrists
• Fever – sudden onset, biphasic with a period of
remission of 1-6 days of fever
• Lymphadenopathy
• Conjuctivitis
• Rash and Hemorrhagic tendencies.
Treatment
supportive
ZIKA VIRUS
• Zika virus infection is a mild febrile viral illness transmitted by mosquitoes.
• The Zika virus is a member of the Flavivirus genus in the family Flaviviridae.
• It is related to dengue, yellow fever, West Nile and Japanese encephalitis,
viruses that are also members of the virus family Flaviviridae..
• It was discovered in the Zika forest in Uganda in 1947.
• The Zika virus' incubation period is about 3 to 12 days after the bite of an
infected mosquito.
• Zika virus is transmitted to people primarily through the bite of an infected
Aedes species mosquito (A. aegypti and A. albopictus).
• also transmitted From mother to child.
Symptoms
• Low-grade fever (between 37.8°C and 38.5°C)
• Arthralgia, notably of small joints of hands and feet, with possible swollen
joints
• Myalgia
• Headache, retro-ocular headaches
• Conjunctivitis
• Cutaneous maculopapular rash
• Post-infection asthenia which seems to be frequent.
• More rarely observed symptoms include Abdominal
pain,Diarrhea,Constipation ,mucous membrane Ulcerations, Pruritus
• According to pediatric neurologists in Brazil that some pregnant women
infected by zika virus have given birth to the babies with a birth defect called
microcephaly.
Diagnosis
• IgM, IgG and PCR for Zika virus.
• acute serum (taken within 5 days of symptom onset) and convalescent serum
(2–3 weeks later) should be taken. The two samples are important to rule out
false positive tests due tocross reactivity with similar viruses such as Dengue
Treatment
• There is no commercial vaccine or specific antiviral drug treatment for Zika
virus infection.
• Treatment is directed primarily at relieving symptoms using anti-pyretics and
analgesics.
Diseases transmitted by flies
• Kala azar
• sand fly fever
• oryza fever
• Onchocerciasis
• African sleeping sickness
• Loiasis
• Tularemia
LEISMANIASIS
• it is a protozoal diseases Named after Leishman - First identified the
organisms in 1901.
• Endemic in 4 states in India:
Bihar, Jharkhand,West Bengal,Uttar Pradesh.
• Group of diseases due to infection withLeishmania which is
transmitted by sandflies.
• Reservoir: man, dogs, wild rodents & foxes.
• Vector: several species of sandflies.
Major pathogens
Life cycle
clinical features
Incubation period: Extremely variable (10 days - 3 to 8 months – 2yrs)
Varied presentation:
• Cutaneous
• Diffuse cutaneous
• Mucocutaneous
• Visceral Leishmaniasis (Kala Azar)
cutaneous leishmaniasis
agent-L.Tropica
Typical lesion : Develops at the site where promastigotes areinjected by
the vector
• papule - papule enlarges – ulcerates
MUCOCUTANEOUS LEISHMANIASIS
• agentLeishmania braziliensis
• Begins with nasal stuffiness, inflammation,Ulceration of the
nasal mucosa and septum follows.
• The lips, cheeks, soft palate, pharynx and larynx may
eventually be involved, resulting in substantial
disfigurement.
VISCERAL LEISHMANIASIS (KALA AZAR)
• agent: L. donovani
• Chronic infection with fever,hepatosplenomegaly,
lymphadenopathy & anaemia.
• There is progressive emaciation & weakness with generally
fatal outcome if not treated.
DIAGNOSIS
• Parasite Identification-Demonstration of Leishmania bodies in stained
smear of ulcer, organ or blood
• Serology-Anti-leishmanial antibody titers
• Skin Test-Intradermal leishmanin (Montenegro) skin test
• Aldehyde test
Treatment
Antimony-containingcompounds-
• meglumine antimonate-CL,VL,MCL
• sodium stibogluconate.-CL,MCL,VL
Other drugs -
• Pentamidine:CL
• amphotericin
PKDL
• Some patients in India and Africa develop skin lesions following treatment,
ranging from hyperpigmented maculesto frank nodules
• Skin lesions typically appear 1 or 2 years after treatment andmay persist for as
long as 20 years.
• Persistence of lesions beyond one year is associated with highanti - leishmanial
antibody titers and negative leishmanial skintest responses
• Anti - leishmanial treatment is indicated in Indian PKDL
Onchocerciasis
• Onchocerciasis caused by Onchocerca volvulus a filarial worm.
• Commonly known as river blindness / Robles' disease,
• Transmitted by blackflies of the similium species flies breed in fast-
flowing streams and rivers.
life cycle
Pathology and pathogenesis
• Microfilariae released from the female worms that cause the most severe damage
• Migrating microfilariae, exclusively found in the interstitial fluids of the skin and
subdermal tissues (not thebloodstream),
• Cause
• changes in skin pigment
• loss of elastic fibers, “hanging groin,”
• severe pruritus.
• accumulation of microfilariae in the vitreous humor.
• Visual clouding, photophobia, and ultimately retinal damage result in incurable
blindness.
Clinical features
• Intense itching
• Depigmentation of the skin
• Elephant skin
• Blindness
• Rashes
• Lesions
• Lymphadenitis
• General debilitation
• Serious visual impairment
Diagnosis
• Slit-lamp examination of the anterior segment of the eye.
• Surgical removal and examination of nodules.
• Serological test.
Management
• ivermectin (mectizan) is administered as an oral dose of 150 micrograms per
kilogram(maximum 12 mg) every 6-12 months.
• Doxycycline is used to kill the wolbabchia bacteria that live in adult worms
• surgical removal of the nodules.
Trypanosomiasis
• caused by Trypanosoma Brucei Gambiense.
• First isolated in 1901 by Forde.
• It is endemic in West and Central Africa
• Habitat: They live in man and other vertebrate hosts. They are
parasites of connective tissue.
• Morphology- 2 forms
Vertebrate Forms-trypomastigote
Insect Forms-Epimastigotes, Metacyclic trypomastigote.
Life Cycle
• T. brucei gambiense passes its lifecycle in 2 hosts.
– Vertebrate host: Man, game animals, andother domestic animals.
– Invertebrate host: Tsetse fly.
• Both male and female tsetse fly arecapable of transmitting the disease
tohumans.
• Infective form: Metacyclic trypomastigote.
• Mode of transmission:– By bite of tsetse fly
• Reservoirs: Man is the only reservoirhost, although pigs and others domestic
animals can act as chronic asymptomatic carriers of the parasite.
Life Cycle
Signs and Symptoms
• Anxiety
• Mood changes
• Fever
• Headache
• Weakness
• Insomnia at night
• Sleepiness during the day (may be uncontrollable)
• Sweating
• Swollen lymph nodes all over the body
• Swollen, red, painful nodule at site of the fly bite
Laboratory Diagnosis
Nonspecific Findings
• Anemia and monocytosis.
• Raised ESR due to rise in gamma globulinlevels.
• Reversal of albumin:globulin ratio.
• Increased cerebrospinal fluid (CSF) pressure and raised cell count and proteins in
CSF.
Specific Findings
• Definitive diagnosis of sleeping sicknessis established by the demonstration of
trypanosomes in peripheral blood, bonemarrow, lymphnode, CSF, and chancre
fluid.
Treatment
• pentamidine
• suramin
Loiasis
• caused by Loa Loa.
• also known as african eye worm
• Definitive Host: human
• Intermediate Host: horsefly genus Chrysops.
Diseases
1.LOIASIS is often asymptomatic.
2. Episodic angioedema and subconjunctival
migration of an adult worm can occur.
3. Calabar swelling.
life cycle
LAB DIAGNOSIS
• Definitive diagnosis include
Detection of microfilaria in peripheral smear 12 - 2pm (diurnal periodicity)
• Isolation of adult worm from eye,Skin,Conjunctiva,subcutaneous biopsy
specimen
• High eosinophilic count
TREATMENT
• DEC 8-10mg/kg per day for 21 days
• Ivermectine or albendazole is effective in reducing filarial load
• Surgical removal of adult worm .
Diseases transmitted by ticks
HARD TICK
• KFD
• tick paralysis
• Babeseosis
SOFT TICK
• Q fever
• Relapsing fever
Kyasanur Forest Disease
• Kyasanur forest disease (KFD) is a febrile disease associated with hemorrhages caused
by an flavivirus.
• KFD virus is a member of group B togaviruses Found in India Limited originally to
Shimoga district in Karnataka.
• rats, squirrels, shrews and bats are the main reservoirs.
• Monkeys are the amplifying hosts for the virus
• Hard tickspecies of the genusHaemophysalis particularly H.spinigera and H.turtura are
the main vectors
Natural cycle
• In enzootic states the infection is maintained in small mammals and also in ticks
• When monkeys come in contact with infected ticks ,they get infected , amplify and
disseminate the infection in “hot spots ”of infection
• Humans in these hot spots are infected by bite of infected anthrophilic ticks like H.
spinigera
CLINICAL FEATURES
• Acute phase with sudden onset of fever, headache severe myalgia with
prostation lasting for 2 weeks.
• GI disturbances and hemorrhagic manifestations in severe cases
• Second phase characterized by mild meningoencephalitis after an afebrile
period of 7-21 days.
Diagnosis
• Diagnosis by suspicion by clinical signs and symptoms
• H/O occupation/travel in forests
• Detecting the presence of virus in blood.
• Serological evidence by haemagglutination and immunofloresence
Treatment
Conservative
• Antipyretics
• Analgesics
• Supportive therapy
Lyme Disease
• Causative agent: Borrelia burgdorferi
• Reservoir host: Ixodes scapularis
• Ixodes ticks have a 2-year life cycle
• Once a tick is infected, it remains infected for the rest of its life & can transmit
bacteria to other hosts whilefeeding at a later life stage
• Nymphs more likely to feed on humans than adult ticks.
Clinical Features
3 stages
Early localized stage
Early disseminatedstage
Late stage
Clinical Features
• Early localized Lyme disease is marked by erythema
migrans; may develop a "bullseye" appearance as
the rash enlarges; occurs in 70-80% of infected
persons .
• Early disseminated symptoms also include fatigue,
chillsand fever, headache, muscle and joint pain,
swollenlymph nodes, facial palsy, and irregular
heart beat orheart palpitations (Lyme carditis).
• Late stage symptoms include arthritis, numbness,
nervepain or paralysis, meningitis, and problems
with memoryor concentration.
Q FEVER
• It is caused by Coxiella burnetii.
• Obligate intracellular, gram negative bacterium.
• Q stands for Query
• Discovered in 1937 in Queensland, Australia (slaughterhouse workers).
Transmission
ticks
Inhalation (most common)
Direct orindirect contact with infected animal
Primary reservoirs
Sheep, cattle, goats
clinical features
• Incubation: 2 to 4 weeks
disease includes
• 50%-Asymptomatic
• Acute
• Chronic
Acute Infection
• Flu like symptoms: high fever (up to 104-105◦F), headache, sore throat,
vomiting, nausea, fatigue.
• Pneumonia with mild cough (50%)
• Less common Hepatitis, myocarditis, central nervous system complications
• Chronic Disease (> 6 months)
• in 1-5% of acutely infected individuals
• Pre existing heart conditions, pregnant women, immunocompromised
• Endocarditis (60-70%)
Other
• Aortic aneursyms
• Osteomyelitis
Risk to Pregnant Women
Most asymptomatic (98%)
Transplacental transmission lead to
Reported complications
• Premature birth,Low birth weight,Miscarriage,Placentitis.
• Greatest risk during 1sttrimester
Diagnosis
• Serology (most common method)
IFA, CF, ELISA, microagglutination
• DNA detection methods
PCR
• Isolation of organism
Treatment
Acute disease
• Doxycycline (2-3 weeks)
Chronic disease
• Doxycycline and hydroxychloroquine (~18 months)
Tick Paralysis
• Results from neurotoxin in tick
saliva
• Symptoms start within 2-7 days,
beginningwith weakness in both
legs progressing toparalysis
• Paralysis ascends within hours –
may leadto respiratory failure &
death
• Treatment – removal of
embedded tick
TULAREMIA
• Tularemia is a rare infectious disease that can attack the skin,eyes,
lymph nodes, lungs and, less often, other internal organs. Often called
rabbit fever or deer fly fever, tularemia is caused by the bacterium
Francisella tularensis.
• Ticks and deer flies are most likely to transmit the disease to humans
SIGNS & SYMPTOMS
• Ulceroglandular tularemia
• A skin ulcer that forms at the site of infection — usually an insect or
animal bite
• Swollen and painful lymph glands Fever, Chills,Headache, Exhaustion.
Glandular tularemia
• samesigns and symptoms of ulceroglandular tularemia, except no skin
ulcers.
Oculoglandular tularemia
• Eye pain,Eye redness,Eye swelling and discharge,An ulcer on the
inside of the eyelid.
Oropharyngeal tularemia
Fever ,Sore throat (pharyngitis),Mouth ulcers ,Vomiting, Diarrhea
Pneumonic tularemia
• Cough ,Chest pain, Difficulty breathing.
COMPLICATIONS
• pneumonia.
• meningitis
• pericarditis.
• osteomyelitis.
TREATMENT
• streptomycin
• gentamicin
• doxycycline
• ciprofloxacim
Diseases transmitted by mite,flea,louse etc
• Plague
• Trench fever
• Epidemic typhus
• Endemic typhus
• rickettsial pox
• scrub typhus
PLAGUE DISEASE
• Plague is a bacterial infection , which Yersinia pestis is the etiological
agent of this disease , and mostly affects lungs , lymph nodes and
blood vessels .
• TRANSMISSION
• Air droplets,Vector borne transmission,Fecal – oral transmission
TYPES OF PLAGUE DISEASE
• BUBONIC PLAGUE DISEASE
• PNEUMONIC PLAGUE DISEASE
• SEPTICEMIC PLAGUE DISEASE
BUBONIC PLAGUE DISEASE
• BUBO is a Greek word which is termed for swollen lymph glands.
• It is the acute inflammation and painful swellings of the lymph nodes.
• It is the most common type of plague.
• It will occur when an infected rodent or flea bites a person.
• Symptoms : sudden high fever , headache , body pain , chills etc.
PNEUMONIC PLAGUE
• It is an another type of plague , which arises from infection of the lungs , it causes coughing
and sneezing.
• Pneumonic plague is the only form of plague that can be transmitted from person to person.
• The course of the disease is rapid , unless diagnosed and treated soon enough , typically within
a few hours.
• Death may follow in one to six days.
• Symptoms : sudden pneumonia , respiratory failure , watery mucus etc.
SEPTICEMIC PLAGUE
• When the bacteria enter the bloodstream directly and multiply there , it is known as septicemic
plague.
• When they are left untreated , both bubonic and pneumonic plague can lead to septicemic
plague.
• Septicemic plague is the least common of their form with a mortality rate close to 100 percent.
• Symptoms : fever , chills , body pain , severe abdominal pain etc.
DIAGNOSIS
• A blood test can identify if the person have septicemic plague.
•A needle is used to take a sample of the fluid in swollen lymph nodes to identify
bubonic plague.
•Endoscopy technique can be used to identify pneumonic plague.
•By using X – ray.
• ANTIBIOTICS : Streptomycin ,tetracycline
• Newer generation of antibiotics :
gentamicin and doxycycline
TRENCH FEVER
• acute febrile illness caused by a gram-negative bacterium
known as Bartonella quintana
• Body lice (Pediculus humanus corporis) are the vectors.
• B.quintana is transmitted when an infected louse excretes
the bacterium onto the host’s skin.
• The excretion is then scratched or rubbed into the skin.
Clinical manifestations
• Headache
• Rash
• Mild fever
• Bone pain (mainly in shins)
• Neck and back pain
• Pain behind the eyes
• Lymphadenopathy
• Bacteremia
• Endocarditis
• Relapsing febrile illness
• (recurrent fever, usually every fifth
day)
TREATMENT
• Penicillins
• Doxycycline
• Tetracycline
• Gentamicin
• Erythromycin
RICKETTSIAL DISEASES
• Rickettsial diseases are considered some of the most covert
emerging or reemerging diseases.
• Hippocrates in 460 BC used the term Typhus, meaning ‘smoke’ to
describe the confused state of intellect i.e. stupor.
• Rickettsia named after HOWARD TAYLOR RICKETTS died of Typhus
fever contracted during his studies discovered Spotted fever Rickettsia
(1906).
• Commonly reported diseases in India are Scrub typhus, Murine
typhus, Indian tick typhus, Q fever.
Rickettsial characteristics
• Obligate intracellular parasite.
• Gram negative pleomorphic bacteria.
• Most are zoonoses spread to humans byarthropods (except Q fever).
• Cannot grow in culture media, but cultivable only in living tissue.
• No human to human transmission.
• Rickettsial infections- classification
Epidemic Typhus
• Rickettsial agent: - Rickettsia prowazekii
• Insect vector :- Louse
• Mammalian Reservoir :- Human, flying squirrels
• Transmission :-
• Human to human via louse vector, directly in blood,
or as the contaminated louse feces is scratched into
the bite wound, or inhalation of infected louse feces
or dust.
• Incubation period: 5-21 days
Symptoms:
• Acute febrile illness
• Headache
• Myalgia
Neurologic manifestations-
• Stupor, delirium
• Vasculitis
• Gangrene
• Rash : 40-80% macular, centrifugal spread,spare palms and soles
Brill –Zinsser disease
This occurs after the person recovered from epidemic
typhus and reactivation of the Rickettsia prowazekii which
remained latent for years.
Murine typhus/Endemic typhus
• Rickettsial agent: -Rickettsia typhi
• Insect Vector: Flea
• Mammalian Reservoir: Rodents
Transmission :-inhalation of infected louse feces or dust.
• inoculation into skin with feces of infected fleas.
• Incubation period: 1-2 weeks
Symptoms:
• Gradual onset- fever,Headache, myalgia, cough
• Rash: maculopapular rash on trunk
Scrub typhus
• Rickettsial agent : Orientia tsutugamushi
• Insect Vector: Mite infective larvae CHIGGERS
• Transmission :- larval forms - chiggers found in areas ofscrub vegetations.
• Common in military and Jungle warfare, farmers
• Mammalian Reservoir: -Rodents
• Incubation period: -10-12 days
Symptoms :-
• Acute onset with chills and Fever, headache, myalgia,Dry cough
• Escher- the punched out ulcer covered with
• black scab –indicates a site of the bite
• Macular rash appears around the 5th day of the bite
• Lymphadenopathy
• Lymphocytosis
• Cardiac and cerebral involvement
Rocky mountain spotted fever
• Rickettsial agent:- R. rickettsii
• Insect Vector: - Tick
• Mammalian Reservoir: -Rodents, dogs
• Incubation period:- 3-7 days
• Symptoms:- Abrupt onset fever, chills, headache, myalgia
• Rash : first appears in extremities, moves centripetally and
• involve palm.
• Mortality: 70% if left untreated in elderly
• Complications:- HSM, jaundice, myocarditis, uremia, ARDS
Rickettsial pox
Diagnostic Techniques
Older techniques
• Giemsa Staining Technique
• Weil-Felix Proteus Agglutination
Test
Newer techniques
• Immunological Assays
• 1. Indirect Immuno-Peroxidase /
• Immunoflouroscent assay
• 2.ELISA
• 3.PCR
• Rapid Detection Kits
• 1.Dip-S-Ticks
• 2.Scrub typhus RCT
• 3.Scrub typhus IgM / IgG Rapid
• Immunochromatographic Assay Multitest
WEIL-FELIX REACTION
• A Weil-Felix reaction is a type of agglutination test in which patients
serum is tested for agglutinins to O antigen of certain non-motile
Proteus and rickettsial strains (OX19, OX2, OXK)
• OX19, OX2 are strains of Proteus vulgaris.
• OXK is the strain of Proteus mirabilis.
PROCEDURE
The Weil-Felix Test can be done as either a slide or a tube test. The
antigens necessary (OX2, OX19, and OXK) can be obtained
commercially.
SLIDE METHOD
On a solid surface (glass slide,tile, card), a small amount (50-100 μL) of the patient’s
serum isplaced. A single drop of the desired antigen is added, and the resulting
suspension is mixedand then rotated for one minute.Visible agglutination is
indicative of a positive result, and corresponds roughly to a titre of1:20. Positive
results can be further titrated using the tube method.
TUBE METHOD
Using 0.25% phenol saline as a diluent, a series oftubes containing two fold dilutions
of patient serum aremade with a final volume of 1 mL. A drop of antigen suspension
is added to each tube, and the mixture isincubated at 50-55 °C for 4-6 hours. A
positive tubewould show visible flocculation or granulation, which is accentuated
when the tube is gently agitated. The titre corresponds to the most dilute tube in
the series that still shows positivity. Generally, a titre of ≥1:320 isconsidered
diagnostic.
INTERPRETATIONS IN WEIL-FELIX REACTION
• Sera from endemic typhus agglutinateOX19, OX2.
• Tick borne spotted fever agglutinate OX19, OX2.
• Scrub Typhus agglutinate OXK strain
• Test is negative in rickettsialpox, trench fever and Q-fever.
• False positive reaction may occur in urinary or other Proteus infections
• Test may be negative in 50 percent scrub typhus
Principles of arthropod control
1)Environmental control
• elimination of breeding places
• Filling and drainage operation
• carefully planned water management
• provision of piped water supply
• Proper disposal of refuse and other wastes
• cleanliness in and around houses.
2)Chemical control
• organochlorine, organo-phosphorus and carbamate
• To avoid undue environmental pollution, replace gradually the highly persistent
compounds such as DDT with "biodegradable" and less toxic methoxychlor, abate
and dursban.
3)Biological control
• use of larvivorous fish especially Gambusia.
4)Genetic control
• sterile male technique, cytoplasmic incompatibility and chromosomal
translocations
5)Newer methods
• insect growth regulators
• chemosterilants, and
• sex attractants or pheromones
MOSQUITO CONTROL MEASURES
1 ANTI-LARVAL MEASURES
• Environmental control
• Chemical control
• Biological control.
2 ANTI-ADULT MEASURES
• Residual sprays
• Space sprays
• Genetic control.
3 PROTECTION AGAINST MOSQUITO BITES
• Mosquito net
• Screening
• Repellents
ANTI-LARVAL MEASURES
Environmental control
• “source reduction”, and comprises minor engineering methods such
as filling, levelling and drainage of breeding places; and water
management
• adequate collection,removal and disposal of sewage and waste water.
• get rid of water holding containers such as discarded tins, empty pots,
broken bottles,coconut shells and similar other artificial collections of
water.
• aquatic plants to which the larvae attach themselves should be
removed or destroyed by herbicides.
Chemical control
Mineral oils
• widely used are the
diesel oil, fueloil,
kerosene and various
fractions of crude oils
• application rate for oils
is 40 to 90 litres per
hectare
Paris green
• Paris green orcopper
acetoarsenite is an
emerald green, micro-
crystalline powder
practically insoluble in
water
• kills mainly the
Anopheles larva
because they are
surface-feeders.
• Recommended dose is 1
kg of actual paris green
per hectare of water
surface
Synthetic
insecticides
• Fenthion,(22-112)
Chlorpyrifos(11-16), and
Abate(56-112)
• concentration of 1.ppm
has been found to be a
very effective larvicide,
and also the least toxic
Biological control
• Gambusia a/finis and
• Lebister reticulatus (sometimes
known as Barbados Millions).
These fish can be used in burrow
pits, sewage oxidation ponds,
ornamental ponds, cisterns and
farm ponds.
ANTI-ADULT MEASURES
Residual sprays g/m2 duration
DDT 1-2 6-12 mo
Lindane 0.5 3 mo
Malathion 2 3 mo
OMS-'-33 2 3 mo
Space sprays
• insecticidal formulation is
sprayed intothe atmosphere in
the form of a mist or fog to kill
insects.
i) Pyrethrum extract-nerve
poison; 1 oz per 1,000 C. ft. of
space
• Residual Insecticides-malathion
and fenitrothion for Ultra low
vol. fogging
Genetic control
• sterile male technique, cytoplasmic incompatibility, chromosomal
translocations, sex distortion, and gene replacement.
PROTECTION AGAINST MOSQUITO BITES
• Mosquito net
• Screening
• Repellents-Diethyltoluamide (deet); for application on the skin
FLY CONTROL MEASURES
Environmental control
• storing garbage,kitchen wastes and other refuse in bins with tight lids,
• efficient collection, removal and disposal of refuse by incineration,
composting or sanitary landfill.
• provision of sanitary latrines, e.g., pit privies,septic tanks, water-seal
latrines and sanitary system.
• stopping open air defecation.
• sanitary disposal of animal excreta, and
• stepping up general sanitation.
Insecticidal control
RESIDUAL SPRAYS
• by DDT (5%), methoxychlor (5%),
• lindane (0.5%), or chlordane (2.5%) sprayed at about
• 5 litres per 100 square metres of surface; for flies resistant to
• diazinon (2%) dimethoate (2.5%), fenthion (2.5%),
• malathion (5%), or ronnel (5%) may be used.
BAITS
• Poisoned baits containing 1 or 2 per cent diazinon, malathion,
dichlorvos,ronnel and dimethoate
CORDS AND RIBBONS
• Cords and strips impregnated with diazinon, fenthion, or dimethoate
Space sprays
• sprays containing pyrethrin and DDT or HCH
Larvicides
• Insecticides such as 0.5% diazinon, 2% dichlorovos, 2% dimethoate or 1 % ronnel applied
at the rate of 28-56 litres per 100
Fly papers
• made by mixing 2 lbs of resin and one pint of castor oil which should be heated together
until the mixture resembles
Protection against flies
• Screening of houses, hospitals, food markets, restaurants
Health education
• Fly control campaigns require organized individual and community effort which is the
basis of a successful public health programme
Control of sandflies
INSECTICIDES
• single application of 1 to 2 g/m2 of DDT or 0.25 g/m2 of lindane has
been found effective
SANITATION
• removal of shrubs and vegetation within 50 yards of human
dwellings, filling upcracks and crevices in walls and floors,and location
of cattle sheds and poultry houses at a fair distance from human
habitations should receive attention
Control of lice
INSECTICIDAL CONTROL
• Head and crab lice : The present recommended treatment is a lotion containing 0.5 per cent
malathion. The lotion should be left on for 12 to 24 hours when the hair can be washed.
Malathion, if correctly used, will kill lice and nits. Dust containing carbaryl is also effective as
louse powder.
• Body Lice : Since lice have become resistant to DDT and HCH, a powder containing1 per cent
malathion will obviously be the treatment of choice.Dust containing carbaryl may also be used
• Personal hygiene:daily bath with soap and water is essential. Women with long hair should
wash and clean their hair frequently. Clothing, towels and sheets should be washed in hot water
and soap and pressed with hot iron.
Autoclaving of clothes and bedding insteam sterilizers may be required for body louse control.
Arthopod vector borne diseases

More Related Content

What's hot (20)

VECTOR CONTROL
VECTOR CONTROLVECTOR CONTROL
VECTOR CONTROL
 
Medical entomology lecture ppt
Medical entomology lecture pptMedical entomology lecture ppt
Medical entomology lecture ppt
 
Lymphatic Filariasis jp
Lymphatic Filariasis jpLymphatic Filariasis jp
Lymphatic Filariasis jp
 
Arthropods of medical importance
Arthropods of medical importanceArthropods of medical importance
Arthropods of medical importance
 
Zoonotic disease
Zoonotic diseaseZoonotic disease
Zoonotic disease
 
medical importance of ARTHROPODS
medical importance of ARTHROPODSmedical importance of ARTHROPODS
medical importance of ARTHROPODS
 
Mosquitoes
MosquitoesMosquitoes
Mosquitoes
 
Arthropode infection
Arthropode infectionArthropode infection
Arthropode infection
 
Filariasis
FilariasisFilariasis
Filariasis
 
Epidemiology of Malaria
Epidemiology of MalariaEpidemiology of Malaria
Epidemiology of Malaria
 
Sandfly notes
Sandfly notesSandfly notes
Sandfly notes
 
Arthropods
ArthropodsArthropods
Arthropods
 
Dracunculiasis
DracunculiasisDracunculiasis
Dracunculiasis
 
vector borne diseases-ASK
vector borne diseases-ASKvector borne diseases-ASK
vector borne diseases-ASK
 
Plague
Plague Plague
Plague
 
Integrated vector control approach Dr Kulrajat Bhasin.
Integrated vector control approach  Dr Kulrajat Bhasin.Integrated vector control approach  Dr Kulrajat Bhasin.
Integrated vector control approach Dr Kulrajat Bhasin.
 
Parasitic infection
Parasitic infectionParasitic infection
Parasitic infection
 
Japanese encephalitis
Japanese encephalitisJapanese encephalitis
Japanese encephalitis
 
Typhus
TyphusTyphus
Typhus
 
Ecology and control of mosquito
Ecology and control of mosquitoEcology and control of mosquito
Ecology and control of mosquito
 

Similar to Arthopod vector borne diseases

Pediatric communicable Diseases
Pediatric communicable DiseasesPediatric communicable Diseases
Pediatric communicable DiseasesAparna Harshan
 
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdfMalaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdfHappychifunda
 
Malaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptxMalaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptxSyedFurqan30
 
Ebola virus main
Ebola virus mainEbola virus main
Ebola virus mainNeha Seth
 
20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptx
20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptx20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptx
20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptxActionForyou
 
Clinical Aspects of Malaria
Clinical Aspects of MalariaClinical Aspects of Malaria
Clinical Aspects of Malariaelhady2000
 
Management of uncomplicated and severe Malaria.pptx
Management of uncomplicated and severe Malaria.pptxManagement of uncomplicated and severe Malaria.pptx
Management of uncomplicated and severe Malaria.pptxDesmond452126
 
malaria-141112210953-conversion-gate02 (1) (1).pptx
malaria-141112210953-conversion-gate02 (1) (1).pptxmalaria-141112210953-conversion-gate02 (1) (1).pptx
malaria-141112210953-conversion-gate02 (1) (1).pptxBhavana519886
 
Samaysingh-Malaria.pptx
Samaysingh-Malaria.pptxSamaysingh-Malaria.pptx
Samaysingh-Malaria.pptxBhavana519886
 

Similar to Arthopod vector borne diseases (20)

Sovran rai
Sovran raiSovran rai
Sovran rai
 
Pediatric communicable Diseases
Pediatric communicable DiseasesPediatric communicable Diseases
Pediatric communicable Diseases
 
Malaria ppt final
Malaria ppt finalMalaria ppt final
Malaria ppt final
 
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdfMalaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
Malaria-Parasitorology, clinical features, pathogenesis and treatment.pdf
 
DRUG OF MALARIA PPT.pptx
DRUG OF MALARIA PPT.pptxDRUG OF MALARIA PPT.pptx
DRUG OF MALARIA PPT.pptx
 
Malaria
MalariaMalaria
Malaria
 
Malaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptxMalaria PPT 1 NEW.pptx
Malaria PPT 1 NEW.pptx
 
Malaria
Malaria Malaria
Malaria
 
Ebola virus main
Ebola virus mainEbola virus main
Ebola virus main
 
20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptx
20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptx20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptx
20230628114955_649c1e63da0c6_chn_presentation_on_dengue (3).pptx
 
Pharmacotherapy of Malaria
Pharmacotherapy of MalariaPharmacotherapy of Malaria
Pharmacotherapy of Malaria
 
Enteric Fever
Enteric FeverEnteric Fever
Enteric Fever
 
MALARIA.pptx
MALARIA.pptxMALARIA.pptx
MALARIA.pptx
 
Malaria ppt.
Malaria ppt.Malaria ppt.
Malaria ppt.
 
Clinical Aspects of Malaria
Clinical Aspects of MalariaClinical Aspects of Malaria
Clinical Aspects of Malaria
 
Management of uncomplicated and severe Malaria.pptx
Management of uncomplicated and severe Malaria.pptxManagement of uncomplicated and severe Malaria.pptx
Management of uncomplicated and severe Malaria.pptx
 
Severe malaria
Severe malariaSevere malaria
Severe malaria
 
malaria-141112210953-conversion-gate02 (1) (1).pptx
malaria-141112210953-conversion-gate02 (1) (1).pptxmalaria-141112210953-conversion-gate02 (1) (1).pptx
malaria-141112210953-conversion-gate02 (1) (1).pptx
 
Samaysingh-Malaria.pptx
Samaysingh-Malaria.pptxSamaysingh-Malaria.pptx
Samaysingh-Malaria.pptx
 
seminar on Malaria
seminar on Malaria seminar on Malaria
seminar on Malaria
 

More from vinay nandimalla

medical therapy of parkinsons disease.pptx
medical therapy of parkinsons disease.pptxmedical therapy of parkinsons disease.pptx
medical therapy of parkinsons disease.pptxvinay nandimalla
 
revasularisation of acute stroke.pptx
revasularisation of acute stroke.pptxrevasularisation of acute stroke.pptx
revasularisation of acute stroke.pptxvinay nandimalla
 
cerebral ischemia and infarction.pptx
cerebral ischemia and infarction.pptxcerebral ischemia and infarction.pptx
cerebral ischemia and infarction.pptxvinay nandimalla
 
Physiology of muscle contraction.pptx
Physiology of muscle contraction.pptxPhysiology of muscle contraction.pptx
Physiology of muscle contraction.pptxvinay nandimalla
 
Dystrophin-glycoprotein-complex PPT.pptx
Dystrophin-glycoprotein-complex PPT.pptxDystrophin-glycoprotein-complex PPT.pptx
Dystrophin-glycoprotein-complex PPT.pptxvinay nandimalla
 
Approach to anemia in children
Approach to anemia in childrenApproach to anemia in children
Approach to anemia in childrenvinay nandimalla
 

More from vinay nandimalla (14)

PAIN PATHWAY.pptx
PAIN PATHWAY.pptxPAIN PATHWAY.pptx
PAIN PATHWAY.pptx
 
medical therapy of parkinsons disease.pptx
medical therapy of parkinsons disease.pptxmedical therapy of parkinsons disease.pptx
medical therapy of parkinsons disease.pptx
 
revasularisation of acute stroke.pptx
revasularisation of acute stroke.pptxrevasularisation of acute stroke.pptx
revasularisation of acute stroke.pptx
 
cerebral ischemia and infarction.pptx
cerebral ischemia and infarction.pptxcerebral ischemia and infarction.pptx
cerebral ischemia and infarction.pptx
 
Physiology of muscle contraction.pptx
Physiology of muscle contraction.pptxPhysiology of muscle contraction.pptx
Physiology of muscle contraction.pptx
 
HYPOTHALAMUS.pptx
HYPOTHALAMUS.pptxHYPOTHALAMUS.pptx
HYPOTHALAMUS.pptx
 
Dystrophin-glycoprotein-complex PPT.pptx
Dystrophin-glycoprotein-complex PPT.pptxDystrophin-glycoprotein-complex PPT.pptx
Dystrophin-glycoprotein-complex PPT.pptx
 
STRUCTURE OF MUSCLE.pptx
STRUCTURE OF MUSCLE.pptxSTRUCTURE OF MUSCLE.pptx
STRUCTURE OF MUSCLE.pptx
 
Approach to anemia in children
Approach to anemia in childrenApproach to anemia in children
Approach to anemia in children
 
How to establish nicu
How to establish nicuHow to establish nicu
How to establish nicu
 
Development of heart
Development of heartDevelopment of heart
Development of heart
 
Hydrocephalus
HydrocephalusHydrocephalus
Hydrocephalus
 
Birth injuries
Birth injuriesBirth injuries
Birth injuries
 
Snake bite in pediatrics
Snake bite in pediatricsSnake bite in pediatrics
Snake bite in pediatrics
 

Recently uploaded

Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxdrashraf369
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptxDr.Nusrat Tariq
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.ANJALI
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 

Recently uploaded (20)

Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
low cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptxlow cost antibiotic cement nail for infected non union.pptx
low cost antibiotic cement nail for infected non union.pptx
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
Glomerular Filtration and determinants of glomerular filtration .pptx
Glomerular Filtration and  determinants of glomerular filtration .pptxGlomerular Filtration and  determinants of glomerular filtration .pptx
Glomerular Filtration and determinants of glomerular filtration .pptx
 
Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.Statistical modeling in pharmaceutical research and development.
Statistical modeling in pharmaceutical research and development.
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 

Arthopod vector borne diseases

  • 1. ARTHOPOD VECTOR BORNE DISEASES Dr. N.Vinay Kumar Under the guidance of Dr. J M Pawar sir
  • 2. ARTHROPOD • Arthropod is a Greek word meaning Jointe Leg(Arthron:joint,pod:foot) • It is an invertebrate animal having an exoskeleton, a segmented body and paired body appendages. VECTOR • A vector is an organism that does not cause disease in itself ,but does spread the parasite to other life forms.
  • 3. Arthopods of medical importance
  • 4.
  • 5. Transmission of arthopod vector borne diseases 1)Direct contact-eg.scabies,pediculosis 2)Mechanical trasmission-eg.diarrhoes,dysentry 3)Biological transmission-3 types a)propagative -eg.plague bacilli in ratflea b)cyclo-developmental-eg.filarial larva in culex c)cyclo-propagative -eg.malarrial parasite in anopheles
  • 6. Diseases transmitted by vectors ANOPHELES • Malaria • Lymphatic filariasis CULEX • Lymphatic filariasis • Japanese encephalitis AEDES • Yellow fever • Dengue fever • Chikungunya • Zika MANSONIA • Lymphatic filariasis TseTse fly • African sleeping sickness BLACK FLY • Onchocerciasis SAND FLY • Kala azar • sand fly fever • oryza fever HORSE FLY • Loiasis
  • 7. HARD TICK • KFD • tick paralysis • Tularemia • Lyme disease • Babeseosis SOFT TICK • Q fever • Relapsing fever REDUVID BUG • Chagas disease RAT FLEA • Plague • Endemic typhus LOUSE • Relapsing fever • Epidemic typhus • Trench fever MITE • rickettsial pox • scrub typhus
  • 8. Diseases transmitted by mosquitos • Malaria • Lymphatic filariasis • Japanese encephalitis • Yellow fever • Dengue fever • Chikungunya • Zika
  • 10. Malaria • Name is derived from Italian Mal’ aria or bad air • 1880 - Charles Louis Alphose Lavern discovered malarial parasite in wet mount. • 1898 - Roland Ross - Life cycle of parasite transmission, wins Nobel Prize in 1902 • Malaria is a vector-borne infectious disease caused by single-celled protozoan parasites of the genus Plasmodium. • Malaria is transmitted from person to person by the bite of female mosquitoes. Etiology of Malaria Four Species known to infect Man 1 Plasmodium vivax 2 P.ovale 3 P.malariae 4 P.falciparum
  • 12. clinical manifestations UNCOMPLICATED MALARIA First symptoms are non specific: • Headache, Lassitude, Fatigue • Abdominal discomfort, muscle and joint aches, diarrhea • Followed by fever(irregular at first), chills, rigors, perspiration, anorexia . In some cases palpable spleen and slight enlargement of liver are also present • Nausea,vomiting, & orthostatic hypotension are common Signs: • Anemia, splenomegaly, hepatomegaly
  • 13. SEVERE FALCIPARUM MALARIA • Unarousable Coma / cerebral malaria, convulsions • Renal Impairment • Noncardiogenic pulmonary edema • Liver Dysfunction • Hypoglycemia • Metabolic acidosis/acidemia • Hematological abnormality like hemoglobinuria, normocytic anemia, bleeding,DIC • Other complications like jaundice, extreme weakness,hyperparasitemia, impaired consciousness • Hypotension/shock
  • 14. complications • Cerebral malaria • Renal failure • Non cardiogenic pulmonary oedema • Hypoglycemia • Acidosis • Haematologic abnormalities • Algid malaria • Tropical splenomegaly • Quartan malarial nephropathy
  • 15. CEREBRAL MALARIA • Coma is characteristic and ominous feature of falciparum malaria • Manifests as diffuse encephalopathy • No signs of meningeal irritation • Muscle tone : May be Increased/ Decreased • Tendon reflexes : Variable, Plantars : Equivocal. • Abdominal & cremasteric reflexes are absent • Fundus : Retinal hemorrhages, discreet spots ofretinal opacification, papilledema, cotton wool spots • Convulsions :In children, usually generalised, often repeated • Residual neurological deficit(Hemiplegia, CP, cortical blindness, deafness, impaired cognition and learning) seen in children who survive cerbral malaria
  • 16. Diagnosis Clinical • Fever, sweat, chills, headache and muscle pain Serology • PCR • ELISA Blood Film (gold standard) • Banana-shaped intraerythrocytic gametocytes identify P. falciparum • Enlarged erythrocytes with Schuffner’s dots are characteristics of P. vivax • Schuffner’s dots in ovale-shaped red blood cells are characteristic of P. ovale • Band-form trophozoites are seen in P. malariae
  • 17. TREATMENT All Plasmodium species except chloroquine resistant falciparum malaria Oral Drug of Choice • Chloroquine phosphate10 mg base/kg (maximum: 600 mg base) then 5 mg base/kg (maximum: 300 mg base), 6 hr later,24 and 48 hr. Parenteral Drug of Choice • Quinidine gluconate10 mg/kg loading dose(maximum: 600 mg) over 1-2 hr, then 0.02 mg/kg/min continuous infusion until oral therapy can be started Or • Quinine dihydrochloride 20 mg/kg loading dose over 4 hr, then 10 mg/kg over 2-4 hr q8h (maximum: 1,800mg/24 hr) until oral therapy can be started
  • 18. Chloroquine resistant Faliciparum Malaria Oral Regimen of Choice  Quinine sulfate 30 mg/kg/24 hr divided in three doses for 3-7 days (maximum: 650 mg/dose) plus Tetracycline 20 mg/kg/24 hr divided in four doses for 7 days (maximum: 250 mg/dose). • Mefloquine hydrochloride15 mg PO followed by 10 mg/kg PO 8-12 hours later (maximum: 1,250 mg) for 1 day. Parenteral • Quinidine gluconateSame as for chloroquine-sensitive P. Falciparum or • Quinine dihydrochlorideSame as for chloroquine-sensitive P. falciparum. Prevention of Relapses Plasmodium vivax and Plasmodium ovaleOnly • Primaquine phosphate
  • 19. ARTEMISINS • Artemisinin derivatives clear parasitemia morerapidly than quinine . They are active against abroader life-cycle range of blood stage parasitesthan quinine and they are active against gametocytes . • Artemisinin derivatives include artesunate , artemether and artemotil. Artesunate is thepreferred artemisinin; clinical experience with artemether and artemotil drugs is limited and they should not be used for treatment of severedisease. The standard dosing regimen for intravenous artesunate consists of five doses: • 2.4 mg/kg as the first dose, followed by • 2.4 mg/kg at 12 and 24 hours, followed by • 2.4 mg/kg once daily
  • 20.
  • 21. Lymphatic Filariasis • Filariasis is the pathological condition caused by infection of filarial nematodes transmitted by different vectors. • Infection with 3 closely related Nematodes 1) Wuchereria bancrofti 2) Brugia malayi 3)Brugia timori Vectors of lymphatic filariasis The major vectors of W. bancrofti are mosquitoesof the genus Culex , Anopheles and Aedes. The vectors of B. malayi are transmitted by Mansonia; in some areas,anopheline mosquitoes.
  • 23. Clinical manifestations • Asymptomatic amicrofilaraemia :exposed people in endemic area do not show Mf or clinical manifestation of disease. • Asymptomatic microfilaraemia: blood is positive for Mf, but no symptoms. carriers. • Stage of acute manifestation: recurrent episode of acute inflammation in lymph gland and vessels.Filarial fever, lymphangitis, lymphadenitis,lymphoedema and epididymoorchitis. • Stage of chronic obstructive lesion:develops 10- 15 yrs after acute attack. mainly due to fibrosis and obstruction of lymphatic vessel, causing permanent structural change. Hydrocele, elephantiasis and chyluria.
  • 24. LABORATORY DIAGNOSIS • Samples includes : Peripheral blood , Chylous urine, Exudate of lymph varix, Hydrocele fluid,Lymph node biopsy, skin specimen • Microscopic examination : It deals with the detection of microfilariae. • Macroscopic examination : detection of adult worm ( lypmh node biopsy ) • Haematological examination : eosoinophilic count is done. • Serological test : Complement fixation test is performed. • Intradermal test : immediate hypersensitivity test. Filarial antigen is injected on skin. After 30 minutes a wheal over 2 cm appears.
  • 25. Treatment • Diethyl carbamazepine is the drug of choice for Lymphatic filariasis. • It is filaricidal in action. 1st day—50 mg . 2nd day---50 mg tid . 3rd day--- 100 mg tid. 4th day to 21st day– 5mg/kg /day in 3 divided doses. • Use of tetracycline to kill the adult worm & to kill wolbachia bacteria which is having a symbiotic relation with W.bancrofti. • Other drugs include: Ivermectin-single oral dose-150μg/kg is used to destroy the Mf, but not the adult worm. • Recently evaluated drugs include Levamisole, mebendazole and centprazine.
  • 26. JAPANESE ENCEPHALITIS • Japanese encephalitis is a mosquito-borne viral infection. • Japanese Encephalitis is the inflammation of brain,due to Group B Arbo virus transmitted by Culex mosquitoes. • It is directly affect to the central nervous system and may cause severe complications. Agent Group B Arbo virus in the genus group of Flaviviridae. Host All age groups & Both genderMore in children under 15 years of age. vector Culex tritaeniorhynchus,c.vishnii reservoir Domestic pigs and wild birds(especially herons) are reservoirs of the virus. Incubation Period 5-15 days.
  • 28. clinical features 1. Prodromal stage 2. Acute Encephalitic stage 3. Late stage Prodromal stageThe onset of illness is usually acute & the duration of this stage is usually 1-6 days. • Fever(38-41’c) • Headache • Rigors (Intensive shivering) • GI disturbances • Nausea & Vomiting • Lethargy Acute Encephalitic stage This stage begins by 3-5th day • High grade fever • Nuchal rigidity • Convulsions signs of increased ICP • Unconsciousness • Dystonia • Dysphasia • Hemiplegia • Quadriplegia
  • 29. Late stage • This stage begins when activeinflammation reducedie,the temperature & ESR touch normal. • CNS involvement is more in this stage. • Mental impairment • Epilepsy • Behavioural abnormalities. • The average period between the onset of illness and death is about 9 days .
  • 30. Treatment • supportive treatment (anti pyretics,anticonvulsants,diuretics etc) VACCINATION 3 types of JE vaccines: 1. Mouse Brain-derived Purified &Inactivated Vaccine (Nakayama or Beijing strain of JE virus) 2. Cell Culture Derived Inactivated JE Vaccine (Beijing P-3 strain) 3. Cell Culture Derived, Live Attenuated Vaccine ( SA 14 – 14 – 2 strain of JE virus)
  • 31. Yellow Fever • Yellow fever is a mosquito-borne acute febrile illness accompanied by hepatic necrosis. • It occurs mainly in tropical Africa and Latin America. • It does not exist in India. • The name has been derived from ‘yellow quarantine flag’ used by the ships during 17th century to warn the presence, on board of this infection. • Yellow fever occurs in 2 major forms: urban and jungle (sylvatic) cycle. • In the urban cycle, man serves both as reservoir and as definitive host, the virus being transmitted by Aedes aegypti mosquito • In the forest or sylvatic cycle, wild monkeys act as reservoirs and several species of forest mosquitos are vectors. Human cases occur only when humans trespass into the forest or when monkeys raidvillages
  • 32. Pathogenesis • After introduction into the skin by the mosquito-bite, the virus multiplies locally and spreads to the local lymphnodes where it multiplies. • From the lymphnodes, it enters the circulating blood. The virus starts appearing in blood 3-6 days after the bite ofinfected mosquito and viraemia lasts for 4-5 days. • From blood, the virus becomes localised in the liver,spleen, kidney, bonemarrow and myocardium, where it may persist for days. • The lesions of yellow fever are due to the localization and propagation of the virus in a particular organs.
  • 33. Clinical features • After an incubation period of 3-6 days, patient develops fever with chills, headache, myalgia and vomiting. • Most cases are mild in nature, especially in the endemic areas, in whom the disease may present as undifferentiated fever without jaundice. • The pulse is usually slow despite a high temperature. • In 15-20% of cases, the disease progresses to a more serious form with jaundice, albuminuria, renal failure and haemorrhagic manifestations and the patient may die of hepatic and renal failure.
  • 34. Laboratory diagnosis Detection of viral antigen • Viral antigen or nucleic acid can be detected in tissue specimen using ELISA, PCR, and immunohistochemistry Isolation of virus • Virus can be isolated from blood in the first 4 days after onset or from postmortem tissue by intracerebral inoculation of mice or inoculating cell lines Postmortem diagnosis • There is severe midzonal degeneration, necrosis andacidophilic inclusion bodies seen in the liver Serology • During first week of illness, IgM antibody can be detected by ELISA
  • 35. Prophylaxis • There is no antiviral drug against yellow fever • The control of urban yellow fever can be achieved by eradicating the vector mosquito • Two vaccines have been developed for human use 1. The french neurotropic vaccine (Dakar) produced from infected mouse brain. 2. 17D vaccine developed by Theiler in 1937 . • Live attenuated vaccine “non virulent strain cultivated on chick embryo & subsequently freeze dried”. Vaccine is stored at -25°C. • Single dose, 0.5ml, S.C. injection. • effectiveness start after 10days & persists for 10 years & then reimmunization is required.
  • 36. VACCINATION CERTIFICATE a. Is required from all international travelers including childrencoming from or going to endemic areas "Yellow Fever belt". b. Validity starts 10 days after primo-vaccination & lasts for 10 ys. c. Validity starts on same day after re-vaccination & lasts for 10 ys. d. If no certificate is available: traveler is isolated for 6 days from date of leaving endemic area.
  • 37. Dengue • Dengue fever is clinically similar to the illness caused by the chikungunya and O’nyong-nyong viruses. • Dengue virus is widely distributed in the Caribbean region, south east asia. • In India first outbreak of dengue was recorded in 1812. • In New Delhi, outbreaks of dengue fever reported in 1967,1970,1982, &1996. Morphology of Dengue virus • spherical,Contains a single plus strand of RNA surrounded by a lipid bilayer. • The E (envelope), M (membrane) and C (capsid) proteins
  • 38. Etiology types • Four distinct antigenically related serotypes ( 1to 4) of dengue virus of the family flaviviridae are etiologically responsible. • Infection in human by one serotypes produces life long immunity against re-infection by the same serotype. • All 4 types of dengue viruses are present in India. • Subsequent infection with other serotypes may result in a severe illness i. e., dengue haemorrhagic fever or dengue shock syndrome. • Dengue transmitted by infected female Aedes mosquito.
  • 39. Pathogenesis 1.The virus is inoculated into humans with the mosquito saliva. 2.The virus localizes andreplicates in various organs,for example, local lymph nodes, liver, spleen and the thymus. 3.The virus is then released from these tissues into theblood. 4.Via the blood, the virus spreads throughout the body to infect other lymphatic tissues and organs, which is accompanied by symptoms. 5.The mosquito ingests blood containing the virus. 6.The virus replicates in the mosquito midgut. It then escapes into the body cavity, and later infects the salivary glands. 7.The virus replicates in the salivary glands and when the mosquito bites another human, the cycle continues.
  • 40. Clinical features • The disease may occur in two forms 1. Classical dengue fever (break-bone fever). 2. Dengue in more serious forms with haemorrhagic manifestations (DHF/DSS). Classical dengue fever This usually affects older children and adults • It has relatively benign course with fever, headache, retrobulbarpain, conjunctival infection, pain in muscles and bones,lymphadenopathy and maculopapular rash • The fever is typically biphasic (saddle back) • Incubation period is 5 – 8 days • A maculopapular rash generally appears on 3rd or 4th day • The febrile illness lasts for about 10 days after which recovery is generally complete. It is rarely fatal.
  • 41. Other manifestations Dengue may also occur in more serious forms, with haemorrhagic manifestations or with shock. • DHF/DSS remains mostly confined among children of 5 -10 years age group in area where multiple dengue viruses cause disease. • It appers to be hyperimmune response. • On reinfection with a different serotype of dengue virus, antibody formed against the first virus reacts with the second serotype virus forming immune complexes (virus-antibody complex). • In DHF/DSS, initial symptoms are like those of dengue fever but associated with haemorrhagic rash, thrombocytopenia and shock
  • 42. Clinical Case Definition for Dengue Fever • Classical Dengue fever or Break bone fever is an acute febrile viral • disease frequently presenting with headaches, bone or joint pain, • muscular pains,rash,and leucopenia Clinical Case Definition for Dengue Hemorrhagic Fever 4 Necessary Criteria: • 1. Fever, or recent history of acute fever • 2. Hemorrhagic manifestations • 3. Low platelet count (100,000/mm3 or less) • 4. Objective evidence of “leaky capillaries:” elevated hematocrit (20% or more over baseline) ,low albumin, pleural or other effusions Clinical Case Definition for Dengue Shock Syndrome 4 criteria for DHF + Evidence of circulatory failure
  • 43.
  • 44. Hemorrhagic Manifestations of Dengue petechiae, purpura, ecchymoses,Gingival bleeding,Nasal bleeding Hematemesis, melena, hematochezia,Hematuria Laboratory diagnosis 1)Haematological diagnosis-Thrombocytopenia (1,00,000 cells or less per mm3),Haemoconcentration (> 20 % rise in haematocrit). 2)Microbiological diagnosis- • Detection of antibody • Detection of NS1 antigen • Isolation of virus • PCR
  • 45. Dengue fever Management • There is no specific antiviral treatment. • The management is essentially supportive and symptomatic. • The key to success is frequent monitoring and changing strategies depending on clinical and laboratory evaluations • Bed rest, Antipyretics or cold sponging ,Analgesics and mild sedation. Prophylaxis • Control measures include elimination of mosquitoes • No effective vaccine is available • In order to avoid the DHF/DSS in immunised persons, a live attenuated vaccine containing all four dengue serotypes is under clinical trials
  • 46. Chikungunya • The virus is transmitted by Aedes aegypti. • Chikungunya is the native name for the disease in which thepatient lies ‘doubled –up’ due to severe joint pains • First reported Tanzania in 1952 • The virus first appeared in India 1963 when it caused extensive epidemics in Calcutta, Madras, and other areas. • Outbreaks at irregular intervals along east coast of India and Maharashtra till 1973. • It remained quiesent and then reappeared in 2006. • Large outbreak in Andhra and Tamil Nadu which spread to Kerala, Karnataka and Delhi. • There was a reemergence of the chikungunya virus in Indonesia, Schyecelles, Reunioun island of Indian ocean and in India(2006-2007) • due to- 1. Mutation in the E1 glycoprotein of the virus. 2. The virus was being taken up and transmitted byAedes albopiptus.
  • 47. Cinical manifestations Incubation period – 2-3 days • Adults- full blown disease • Crippling joint pains. Migratory polyarthritis mainly affects the small joints of the hands and the wrists • Fever – sudden onset, biphasic with a period of remission of 1-6 days of fever • Lymphadenopathy • Conjuctivitis • Rash and Hemorrhagic tendencies. Treatment supportive
  • 48. ZIKA VIRUS • Zika virus infection is a mild febrile viral illness transmitted by mosquitoes. • The Zika virus is a member of the Flavivirus genus in the family Flaviviridae. • It is related to dengue, yellow fever, West Nile and Japanese encephalitis, viruses that are also members of the virus family Flaviviridae.. • It was discovered in the Zika forest in Uganda in 1947. • The Zika virus' incubation period is about 3 to 12 days after the bite of an infected mosquito. • Zika virus is transmitted to people primarily through the bite of an infected Aedes species mosquito (A. aegypti and A. albopictus). • also transmitted From mother to child.
  • 49. Symptoms • Low-grade fever (between 37.8°C and 38.5°C) • Arthralgia, notably of small joints of hands and feet, with possible swollen joints • Myalgia • Headache, retro-ocular headaches • Conjunctivitis • Cutaneous maculopapular rash • Post-infection asthenia which seems to be frequent. • More rarely observed symptoms include Abdominal pain,Diarrhea,Constipation ,mucous membrane Ulcerations, Pruritus • According to pediatric neurologists in Brazil that some pregnant women infected by zika virus have given birth to the babies with a birth defect called microcephaly.
  • 50. Diagnosis • IgM, IgG and PCR for Zika virus. • acute serum (taken within 5 days of symptom onset) and convalescent serum (2–3 weeks later) should be taken. The two samples are important to rule out false positive tests due tocross reactivity with similar viruses such as Dengue Treatment • There is no commercial vaccine or specific antiviral drug treatment for Zika virus infection. • Treatment is directed primarily at relieving symptoms using anti-pyretics and analgesics.
  • 51. Diseases transmitted by flies • Kala azar • sand fly fever • oryza fever • Onchocerciasis • African sleeping sickness • Loiasis • Tularemia
  • 52. LEISMANIASIS • it is a protozoal diseases Named after Leishman - First identified the organisms in 1901. • Endemic in 4 states in India: Bihar, Jharkhand,West Bengal,Uttar Pradesh. • Group of diseases due to infection withLeishmania which is transmitted by sandflies. • Reservoir: man, dogs, wild rodents & foxes. • Vector: several species of sandflies.
  • 55. clinical features Incubation period: Extremely variable (10 days - 3 to 8 months – 2yrs) Varied presentation: • Cutaneous • Diffuse cutaneous • Mucocutaneous • Visceral Leishmaniasis (Kala Azar) cutaneous leishmaniasis agent-L.Tropica Typical lesion : Develops at the site where promastigotes areinjected by the vector • papule - papule enlarges – ulcerates
  • 56. MUCOCUTANEOUS LEISHMANIASIS • agentLeishmania braziliensis • Begins with nasal stuffiness, inflammation,Ulceration of the nasal mucosa and septum follows. • The lips, cheeks, soft palate, pharynx and larynx may eventually be involved, resulting in substantial disfigurement. VISCERAL LEISHMANIASIS (KALA AZAR) • agent: L. donovani • Chronic infection with fever,hepatosplenomegaly, lymphadenopathy & anaemia. • There is progressive emaciation & weakness with generally fatal outcome if not treated.
  • 57. DIAGNOSIS • Parasite Identification-Demonstration of Leishmania bodies in stained smear of ulcer, organ or blood • Serology-Anti-leishmanial antibody titers • Skin Test-Intradermal leishmanin (Montenegro) skin test • Aldehyde test Treatment Antimony-containingcompounds- • meglumine antimonate-CL,VL,MCL • sodium stibogluconate.-CL,MCL,VL Other drugs - • Pentamidine:CL • amphotericin
  • 58. PKDL • Some patients in India and Africa develop skin lesions following treatment, ranging from hyperpigmented maculesto frank nodules • Skin lesions typically appear 1 or 2 years after treatment andmay persist for as long as 20 years. • Persistence of lesions beyond one year is associated with highanti - leishmanial antibody titers and negative leishmanial skintest responses • Anti - leishmanial treatment is indicated in Indian PKDL
  • 59. Onchocerciasis • Onchocerciasis caused by Onchocerca volvulus a filarial worm. • Commonly known as river blindness / Robles' disease, • Transmitted by blackflies of the similium species flies breed in fast- flowing streams and rivers.
  • 61. Pathology and pathogenesis • Microfilariae released from the female worms that cause the most severe damage • Migrating microfilariae, exclusively found in the interstitial fluids of the skin and subdermal tissues (not thebloodstream), • Cause • changes in skin pigment • loss of elastic fibers, “hanging groin,” • severe pruritus. • accumulation of microfilariae in the vitreous humor. • Visual clouding, photophobia, and ultimately retinal damage result in incurable blindness.
  • 62. Clinical features • Intense itching • Depigmentation of the skin • Elephant skin • Blindness • Rashes • Lesions • Lymphadenitis • General debilitation • Serious visual impairment
  • 63. Diagnosis • Slit-lamp examination of the anterior segment of the eye. • Surgical removal and examination of nodules. • Serological test. Management • ivermectin (mectizan) is administered as an oral dose of 150 micrograms per kilogram(maximum 12 mg) every 6-12 months. • Doxycycline is used to kill the wolbabchia bacteria that live in adult worms • surgical removal of the nodules.
  • 64. Trypanosomiasis • caused by Trypanosoma Brucei Gambiense. • First isolated in 1901 by Forde. • It is endemic in West and Central Africa • Habitat: They live in man and other vertebrate hosts. They are parasites of connective tissue. • Morphology- 2 forms Vertebrate Forms-trypomastigote Insect Forms-Epimastigotes, Metacyclic trypomastigote.
  • 65. Life Cycle • T. brucei gambiense passes its lifecycle in 2 hosts. – Vertebrate host: Man, game animals, andother domestic animals. – Invertebrate host: Tsetse fly. • Both male and female tsetse fly arecapable of transmitting the disease tohumans. • Infective form: Metacyclic trypomastigote. • Mode of transmission:– By bite of tsetse fly • Reservoirs: Man is the only reservoirhost, although pigs and others domestic animals can act as chronic asymptomatic carriers of the parasite.
  • 67. Signs and Symptoms • Anxiety • Mood changes • Fever • Headache • Weakness • Insomnia at night • Sleepiness during the day (may be uncontrollable) • Sweating • Swollen lymph nodes all over the body • Swollen, red, painful nodule at site of the fly bite
  • 68. Laboratory Diagnosis Nonspecific Findings • Anemia and monocytosis. • Raised ESR due to rise in gamma globulinlevels. • Reversal of albumin:globulin ratio. • Increased cerebrospinal fluid (CSF) pressure and raised cell count and proteins in CSF. Specific Findings • Definitive diagnosis of sleeping sicknessis established by the demonstration of trypanosomes in peripheral blood, bonemarrow, lymphnode, CSF, and chancre fluid. Treatment • pentamidine • suramin
  • 69. Loiasis • caused by Loa Loa. • also known as african eye worm • Definitive Host: human • Intermediate Host: horsefly genus Chrysops. Diseases 1.LOIASIS is often asymptomatic. 2. Episodic angioedema and subconjunctival migration of an adult worm can occur. 3. Calabar swelling.
  • 71. LAB DIAGNOSIS • Definitive diagnosis include Detection of microfilaria in peripheral smear 12 - 2pm (diurnal periodicity) • Isolation of adult worm from eye,Skin,Conjunctiva,subcutaneous biopsy specimen • High eosinophilic count TREATMENT • DEC 8-10mg/kg per day for 21 days • Ivermectine or albendazole is effective in reducing filarial load • Surgical removal of adult worm .
  • 72. Diseases transmitted by ticks HARD TICK • KFD • tick paralysis • Babeseosis SOFT TICK • Q fever • Relapsing fever
  • 73. Kyasanur Forest Disease • Kyasanur forest disease (KFD) is a febrile disease associated with hemorrhages caused by an flavivirus. • KFD virus is a member of group B togaviruses Found in India Limited originally to Shimoga district in Karnataka. • rats, squirrels, shrews and bats are the main reservoirs. • Monkeys are the amplifying hosts for the virus • Hard tickspecies of the genusHaemophysalis particularly H.spinigera and H.turtura are the main vectors Natural cycle • In enzootic states the infection is maintained in small mammals and also in ticks • When monkeys come in contact with infected ticks ,they get infected , amplify and disseminate the infection in “hot spots ”of infection • Humans in these hot spots are infected by bite of infected anthrophilic ticks like H. spinigera
  • 74. CLINICAL FEATURES • Acute phase with sudden onset of fever, headache severe myalgia with prostation lasting for 2 weeks. • GI disturbances and hemorrhagic manifestations in severe cases • Second phase characterized by mild meningoencephalitis after an afebrile period of 7-21 days. Diagnosis • Diagnosis by suspicion by clinical signs and symptoms • H/O occupation/travel in forests • Detecting the presence of virus in blood. • Serological evidence by haemagglutination and immunofloresence Treatment Conservative • Antipyretics • Analgesics • Supportive therapy
  • 75. Lyme Disease • Causative agent: Borrelia burgdorferi • Reservoir host: Ixodes scapularis • Ixodes ticks have a 2-year life cycle • Once a tick is infected, it remains infected for the rest of its life & can transmit bacteria to other hosts whilefeeding at a later life stage • Nymphs more likely to feed on humans than adult ticks. Clinical Features 3 stages Early localized stage Early disseminatedstage Late stage
  • 76. Clinical Features • Early localized Lyme disease is marked by erythema migrans; may develop a "bullseye" appearance as the rash enlarges; occurs in 70-80% of infected persons . • Early disseminated symptoms also include fatigue, chillsand fever, headache, muscle and joint pain, swollenlymph nodes, facial palsy, and irregular heart beat orheart palpitations (Lyme carditis). • Late stage symptoms include arthritis, numbness, nervepain or paralysis, meningitis, and problems with memoryor concentration.
  • 77. Q FEVER • It is caused by Coxiella burnetii. • Obligate intracellular, gram negative bacterium. • Q stands for Query • Discovered in 1937 in Queensland, Australia (slaughterhouse workers). Transmission ticks Inhalation (most common) Direct orindirect contact with infected animal Primary reservoirs Sheep, cattle, goats
  • 78. clinical features • Incubation: 2 to 4 weeks disease includes • 50%-Asymptomatic • Acute • Chronic Acute Infection • Flu like symptoms: high fever (up to 104-105◦F), headache, sore throat, vomiting, nausea, fatigue. • Pneumonia with mild cough (50%) • Less common Hepatitis, myocarditis, central nervous system complications
  • 79. • Chronic Disease (> 6 months) • in 1-5% of acutely infected individuals • Pre existing heart conditions, pregnant women, immunocompromised • Endocarditis (60-70%) Other • Aortic aneursyms • Osteomyelitis Risk to Pregnant Women Most asymptomatic (98%) Transplacental transmission lead to Reported complications • Premature birth,Low birth weight,Miscarriage,Placentitis. • Greatest risk during 1sttrimester
  • 80. Diagnosis • Serology (most common method) IFA, CF, ELISA, microagglutination • DNA detection methods PCR • Isolation of organism Treatment Acute disease • Doxycycline (2-3 weeks) Chronic disease • Doxycycline and hydroxychloroquine (~18 months)
  • 81. Tick Paralysis • Results from neurotoxin in tick saliva • Symptoms start within 2-7 days, beginningwith weakness in both legs progressing toparalysis • Paralysis ascends within hours – may leadto respiratory failure & death • Treatment – removal of embedded tick
  • 82. TULAREMIA • Tularemia is a rare infectious disease that can attack the skin,eyes, lymph nodes, lungs and, less often, other internal organs. Often called rabbit fever or deer fly fever, tularemia is caused by the bacterium Francisella tularensis. • Ticks and deer flies are most likely to transmit the disease to humans SIGNS & SYMPTOMS • Ulceroglandular tularemia • A skin ulcer that forms at the site of infection — usually an insect or animal bite • Swollen and painful lymph glands Fever, Chills,Headache, Exhaustion.
  • 83. Glandular tularemia • samesigns and symptoms of ulceroglandular tularemia, except no skin ulcers. Oculoglandular tularemia • Eye pain,Eye redness,Eye swelling and discharge,An ulcer on the inside of the eyelid. Oropharyngeal tularemia Fever ,Sore throat (pharyngitis),Mouth ulcers ,Vomiting, Diarrhea Pneumonic tularemia • Cough ,Chest pain, Difficulty breathing.
  • 84. COMPLICATIONS • pneumonia. • meningitis • pericarditis. • osteomyelitis. TREATMENT • streptomycin • gentamicin • doxycycline • ciprofloxacim
  • 85. Diseases transmitted by mite,flea,louse etc • Plague • Trench fever • Epidemic typhus • Endemic typhus • rickettsial pox • scrub typhus
  • 86. PLAGUE DISEASE • Plague is a bacterial infection , which Yersinia pestis is the etiological agent of this disease , and mostly affects lungs , lymph nodes and blood vessels . • TRANSMISSION • Air droplets,Vector borne transmission,Fecal – oral transmission TYPES OF PLAGUE DISEASE • BUBONIC PLAGUE DISEASE • PNEUMONIC PLAGUE DISEASE • SEPTICEMIC PLAGUE DISEASE
  • 87.
  • 88. BUBONIC PLAGUE DISEASE • BUBO is a Greek word which is termed for swollen lymph glands. • It is the acute inflammation and painful swellings of the lymph nodes. • It is the most common type of plague. • It will occur when an infected rodent or flea bites a person. • Symptoms : sudden high fever , headache , body pain , chills etc. PNEUMONIC PLAGUE • It is an another type of plague , which arises from infection of the lungs , it causes coughing and sneezing. • Pneumonic plague is the only form of plague that can be transmitted from person to person. • The course of the disease is rapid , unless diagnosed and treated soon enough , typically within a few hours. • Death may follow in one to six days. • Symptoms : sudden pneumonia , respiratory failure , watery mucus etc.
  • 89. SEPTICEMIC PLAGUE • When the bacteria enter the bloodstream directly and multiply there , it is known as septicemic plague. • When they are left untreated , both bubonic and pneumonic plague can lead to septicemic plague. • Septicemic plague is the least common of their form with a mortality rate close to 100 percent. • Symptoms : fever , chills , body pain , severe abdominal pain etc. DIAGNOSIS • A blood test can identify if the person have septicemic plague. •A needle is used to take a sample of the fluid in swollen lymph nodes to identify bubonic plague. •Endoscopy technique can be used to identify pneumonic plague. •By using X – ray.
  • 90. • ANTIBIOTICS : Streptomycin ,tetracycline • Newer generation of antibiotics : gentamicin and doxycycline
  • 91. TRENCH FEVER • acute febrile illness caused by a gram-negative bacterium known as Bartonella quintana • Body lice (Pediculus humanus corporis) are the vectors. • B.quintana is transmitted when an infected louse excretes the bacterium onto the host’s skin. • The excretion is then scratched or rubbed into the skin.
  • 92. Clinical manifestations • Headache • Rash • Mild fever • Bone pain (mainly in shins) • Neck and back pain • Pain behind the eyes • Lymphadenopathy • Bacteremia • Endocarditis • Relapsing febrile illness • (recurrent fever, usually every fifth day) TREATMENT • Penicillins • Doxycycline • Tetracycline • Gentamicin • Erythromycin
  • 93. RICKETTSIAL DISEASES • Rickettsial diseases are considered some of the most covert emerging or reemerging diseases. • Hippocrates in 460 BC used the term Typhus, meaning ‘smoke’ to describe the confused state of intellect i.e. stupor. • Rickettsia named after HOWARD TAYLOR RICKETTS died of Typhus fever contracted during his studies discovered Spotted fever Rickettsia (1906). • Commonly reported diseases in India are Scrub typhus, Murine typhus, Indian tick typhus, Q fever.
  • 94. Rickettsial characteristics • Obligate intracellular parasite. • Gram negative pleomorphic bacteria. • Most are zoonoses spread to humans byarthropods (except Q fever). • Cannot grow in culture media, but cultivable only in living tissue. • No human to human transmission. • Rickettsial infections- classification
  • 95. Epidemic Typhus • Rickettsial agent: - Rickettsia prowazekii • Insect vector :- Louse • Mammalian Reservoir :- Human, flying squirrels • Transmission :- • Human to human via louse vector, directly in blood, or as the contaminated louse feces is scratched into the bite wound, or inhalation of infected louse feces or dust. • Incubation period: 5-21 days
  • 96. Symptoms: • Acute febrile illness • Headache • Myalgia Neurologic manifestations- • Stupor, delirium • Vasculitis • Gangrene • Rash : 40-80% macular, centrifugal spread,spare palms and soles Brill –Zinsser disease This occurs after the person recovered from epidemic typhus and reactivation of the Rickettsia prowazekii which remained latent for years.
  • 97. Murine typhus/Endemic typhus • Rickettsial agent: -Rickettsia typhi • Insect Vector: Flea • Mammalian Reservoir: Rodents Transmission :-inhalation of infected louse feces or dust. • inoculation into skin with feces of infected fleas. • Incubation period: 1-2 weeks Symptoms: • Gradual onset- fever,Headache, myalgia, cough • Rash: maculopapular rash on trunk
  • 98. Scrub typhus • Rickettsial agent : Orientia tsutugamushi • Insect Vector: Mite infective larvae CHIGGERS • Transmission :- larval forms - chiggers found in areas ofscrub vegetations. • Common in military and Jungle warfare, farmers • Mammalian Reservoir: -Rodents • Incubation period: -10-12 days Symptoms :- • Acute onset with chills and Fever, headache, myalgia,Dry cough • Escher- the punched out ulcer covered with • black scab –indicates a site of the bite • Macular rash appears around the 5th day of the bite • Lymphadenopathy • Lymphocytosis • Cardiac and cerebral involvement
  • 99. Rocky mountain spotted fever • Rickettsial agent:- R. rickettsii • Insect Vector: - Tick • Mammalian Reservoir: -Rodents, dogs • Incubation period:- 3-7 days • Symptoms:- Abrupt onset fever, chills, headache, myalgia • Rash : first appears in extremities, moves centripetally and • involve palm. • Mortality: 70% if left untreated in elderly • Complications:- HSM, jaundice, myocarditis, uremia, ARDS
  • 101. Diagnostic Techniques Older techniques • Giemsa Staining Technique • Weil-Felix Proteus Agglutination Test Newer techniques • Immunological Assays • 1. Indirect Immuno-Peroxidase / • Immunoflouroscent assay • 2.ELISA • 3.PCR • Rapid Detection Kits • 1.Dip-S-Ticks • 2.Scrub typhus RCT • 3.Scrub typhus IgM / IgG Rapid • Immunochromatographic Assay Multitest
  • 102. WEIL-FELIX REACTION • A Weil-Felix reaction is a type of agglutination test in which patients serum is tested for agglutinins to O antigen of certain non-motile Proteus and rickettsial strains (OX19, OX2, OXK) • OX19, OX2 are strains of Proteus vulgaris. • OXK is the strain of Proteus mirabilis. PROCEDURE The Weil-Felix Test can be done as either a slide or a tube test. The antigens necessary (OX2, OX19, and OXK) can be obtained commercially.
  • 103. SLIDE METHOD On a solid surface (glass slide,tile, card), a small amount (50-100 μL) of the patient’s serum isplaced. A single drop of the desired antigen is added, and the resulting suspension is mixedand then rotated for one minute.Visible agglutination is indicative of a positive result, and corresponds roughly to a titre of1:20. Positive results can be further titrated using the tube method. TUBE METHOD Using 0.25% phenol saline as a diluent, a series oftubes containing two fold dilutions of patient serum aremade with a final volume of 1 mL. A drop of antigen suspension is added to each tube, and the mixture isincubated at 50-55 °C for 4-6 hours. A positive tubewould show visible flocculation or granulation, which is accentuated when the tube is gently agitated. The titre corresponds to the most dilute tube in the series that still shows positivity. Generally, a titre of ≥1:320 isconsidered diagnostic.
  • 104. INTERPRETATIONS IN WEIL-FELIX REACTION • Sera from endemic typhus agglutinateOX19, OX2. • Tick borne spotted fever agglutinate OX19, OX2. • Scrub Typhus agglutinate OXK strain • Test is negative in rickettsialpox, trench fever and Q-fever. • False positive reaction may occur in urinary or other Proteus infections • Test may be negative in 50 percent scrub typhus
  • 105.
  • 106. Principles of arthropod control 1)Environmental control • elimination of breeding places • Filling and drainage operation • carefully planned water management • provision of piped water supply • Proper disposal of refuse and other wastes • cleanliness in and around houses.
  • 107. 2)Chemical control • organochlorine, organo-phosphorus and carbamate • To avoid undue environmental pollution, replace gradually the highly persistent compounds such as DDT with "biodegradable" and less toxic methoxychlor, abate and dursban. 3)Biological control • use of larvivorous fish especially Gambusia. 4)Genetic control • sterile male technique, cytoplasmic incompatibility and chromosomal translocations 5)Newer methods • insect growth regulators • chemosterilants, and • sex attractants or pheromones
  • 108. MOSQUITO CONTROL MEASURES 1 ANTI-LARVAL MEASURES • Environmental control • Chemical control • Biological control. 2 ANTI-ADULT MEASURES • Residual sprays • Space sprays • Genetic control. 3 PROTECTION AGAINST MOSQUITO BITES • Mosquito net • Screening • Repellents
  • 109. ANTI-LARVAL MEASURES Environmental control • “source reduction”, and comprises minor engineering methods such as filling, levelling and drainage of breeding places; and water management • adequate collection,removal and disposal of sewage and waste water. • get rid of water holding containers such as discarded tins, empty pots, broken bottles,coconut shells and similar other artificial collections of water. • aquatic plants to which the larvae attach themselves should be removed or destroyed by herbicides.
  • 110. Chemical control Mineral oils • widely used are the diesel oil, fueloil, kerosene and various fractions of crude oils • application rate for oils is 40 to 90 litres per hectare Paris green • Paris green orcopper acetoarsenite is an emerald green, micro- crystalline powder practically insoluble in water • kills mainly the Anopheles larva because they are surface-feeders. • Recommended dose is 1 kg of actual paris green per hectare of water surface Synthetic insecticides • Fenthion,(22-112) Chlorpyrifos(11-16), and Abate(56-112) • concentration of 1.ppm has been found to be a very effective larvicide, and also the least toxic
  • 111. Biological control • Gambusia a/finis and • Lebister reticulatus (sometimes known as Barbados Millions). These fish can be used in burrow pits, sewage oxidation ponds, ornamental ponds, cisterns and farm ponds.
  • 112. ANTI-ADULT MEASURES Residual sprays g/m2 duration DDT 1-2 6-12 mo Lindane 0.5 3 mo Malathion 2 3 mo OMS-'-33 2 3 mo
  • 113. Space sprays • insecticidal formulation is sprayed intothe atmosphere in the form of a mist or fog to kill insects. i) Pyrethrum extract-nerve poison; 1 oz per 1,000 C. ft. of space • Residual Insecticides-malathion and fenitrothion for Ultra low vol. fogging
  • 114. Genetic control • sterile male technique, cytoplasmic incompatibility, chromosomal translocations, sex distortion, and gene replacement. PROTECTION AGAINST MOSQUITO BITES • Mosquito net • Screening • Repellents-Diethyltoluamide (deet); for application on the skin
  • 115. FLY CONTROL MEASURES Environmental control • storing garbage,kitchen wastes and other refuse in bins with tight lids, • efficient collection, removal and disposal of refuse by incineration, composting or sanitary landfill. • provision of sanitary latrines, e.g., pit privies,septic tanks, water-seal latrines and sanitary system. • stopping open air defecation. • sanitary disposal of animal excreta, and • stepping up general sanitation.
  • 116. Insecticidal control RESIDUAL SPRAYS • by DDT (5%), methoxychlor (5%), • lindane (0.5%), or chlordane (2.5%) sprayed at about • 5 litres per 100 square metres of surface; for flies resistant to • diazinon (2%) dimethoate (2.5%), fenthion (2.5%), • malathion (5%), or ronnel (5%) may be used. BAITS • Poisoned baits containing 1 or 2 per cent diazinon, malathion, dichlorvos,ronnel and dimethoate CORDS AND RIBBONS • Cords and strips impregnated with diazinon, fenthion, or dimethoate
  • 117. Space sprays • sprays containing pyrethrin and DDT or HCH Larvicides • Insecticides such as 0.5% diazinon, 2% dichlorovos, 2% dimethoate or 1 % ronnel applied at the rate of 28-56 litres per 100 Fly papers • made by mixing 2 lbs of resin and one pint of castor oil which should be heated together until the mixture resembles Protection against flies • Screening of houses, hospitals, food markets, restaurants Health education • Fly control campaigns require organized individual and community effort which is the basis of a successful public health programme
  • 118. Control of sandflies INSECTICIDES • single application of 1 to 2 g/m2 of DDT or 0.25 g/m2 of lindane has been found effective SANITATION • removal of shrubs and vegetation within 50 yards of human dwellings, filling upcracks and crevices in walls and floors,and location of cattle sheds and poultry houses at a fair distance from human habitations should receive attention
  • 119. Control of lice INSECTICIDAL CONTROL • Head and crab lice : The present recommended treatment is a lotion containing 0.5 per cent malathion. The lotion should be left on for 12 to 24 hours when the hair can be washed. Malathion, if correctly used, will kill lice and nits. Dust containing carbaryl is also effective as louse powder. • Body Lice : Since lice have become resistant to DDT and HCH, a powder containing1 per cent malathion will obviously be the treatment of choice.Dust containing carbaryl may also be used • Personal hygiene:daily bath with soap and water is essential. Women with long hair should wash and clean their hair frequently. Clothing, towels and sheets should be washed in hot water and soap and pressed with hot iron. Autoclaving of clothes and bedding insteam sterilizers may be required for body louse control.